A new study shows children with achondroplasia, the most common form of dwarfism, grew more than two centimeters per year on ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO® ...
Ascendis Pharma reported new two-year radiographic outcomes from its pivotal ApproaCH trial of TransCon CNP (YUVIWEL) in ...
Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued ...
DWARFISM, otherwise known as restricted growth, is a disability experienced by roughly 6,000 people in the UK. The condition is characterised by short stature and can often result in further medical ...
Dwarfism often happens because of genetic or inherited conditions. Achondroplasia is the most common form of dwarfism, accounting for about 70% of cases. People with achondroplasia have a relatively ...
New findings from a trial conducted at Children's Hospital Colorado (Children's Colorado) and University of Colorado (CU) ...
MedPage Today on MSN
Oral FGFR1-3 Inhibitor Boosted Height Velocity in Common Genetic Growth Disorder
Drug has different mechanism of action than existing injectables ...
A promising daily tablet is effective at increasing height and improving proportional limb growth in children with achondroplasia, the most common form of dwarfism, according to a new study. And the ...
Q: Which doctor can I consult if my baby is diagnosed with achondroplasia? A: You will have to consult a pediatrician, orthopedic surgeon, dental surgeon and a neurosurgeon depending on the ...
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results